December 20th 2016
Professor Jacques Banchereau has joined the company as non-executive director. Professor Banchereau is an internationally prominent immunologist with a 35-year track record of leadership in human academic and industrial research leadership.
Press Release: Ascend appoints Professor Jacques Banchereau as Non-executive director
November 8th 2016
Ascend announces encouraging Phase I/IIa interim results of ASN-002 treatment of Nodular Basal Cell Carcinoma with 100% overall objective response rate for medium and high dose cohorts.
Press Release: ASN-002 Treatment Interim Results
August 11th 2016
Ascend announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Professor Edward Mocarski.
Press Release: Ascend Expands its Scientific Advisory Board
May 2nd 2016
Ascend has entered into an R&D collaboration with leading US Fox Chase Cancer Center based in Philadelphia.
Press Release: Fox Chase Cancer Center Collaboration
March 23rd 2015
Ascend Biopharmaceuticals, has today announced the publication of a report utilising ASN-002 (formerly TG1042) for the treatment of metastatic melanoma patients in the Journal Cancer Immunology Immunotherapy.
Press Release: ASN002 phase II MM results
June 27th 2014
Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has been featured in the 2014 issue of Scientific American Worldview as a case study in immunotherapy treatments.
Press release: Ascend in Scientific American 2014
March 20th 2014
Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has today announced the publication of a report utilising TG1042 (ASN-002) for the treatment of Cutaneous B-Cell Lymphoma (CBCL).
Press Release: ASN-002 demonstrates favourable response in a Phase 2 study
February 14th 2014
Melbourne-based immunotherapy company Ascend Biopharmaceuticals has today welcomed the results of an investigator led follow-up study of patients who participated in a 1998 trial of breast cancer vaccine OM-MUC-1 – an earlier prototype of Ascend’s clinical compound ASN-004.
Press Release: 15-year follow-up study shows strong validation of Ascend’s breast cancer vaccine
November 29th 2013
Ascend Biopharma today announces that is has entered into an agreement with 3M Drug Delivery Systems.
3M and Ascend Press Release
July 9th 2013
Ascend Biopharmaceuticals has signed an agreement with Sigma-Aldrich for its custom manufacturing and services business unit, SAFC, to perform fill, finish and release of ASN-002, a novel cancer immunotherapy.
Ascend SAFC Press Release
Ascend is a cancer immunotherapy company developing medicines to treat primary, recurrent and metastatic cancers. Cancers are made up of many different cell types and a number of these can regulate the local tumour microenvironment to promote tumour growth.
Ascend's strategy focuses on targeting these key cells and to alter the local microenvironment and host response from one that endows tumour growth to one that causes cancer eradication.